These data further confirms that SR4 indirectly activates AMPK by increasing the cellular AMP: ATP ratio

These data further confirms that SR4 indirectly activates AMPK by increasing the cellular AMP: ATP ratio. == Discussion == Our current data describes the pharmacological activity of a novel small molecule dichlorophenyl PE859 urea compound, SR4, in HFD obese mice. acid synthase (Fasn), stearoyl-Coenzyme A desaturase 1 (Scd1), carnitine palmitoyltransferase 1a (Cpt1a) and 3-hydroxy-3-methyl-glutaryl-CoA reductase (Hmgcr), as well as gluconeogenic genes phosphoenolpyruvate carboxykinase 1 (Pck1) and glucose-6-phosphatase (G6pc) in PE859 the liver of obese mice.In vitro, SR4 activates AMPK impartial of upstream kinases liver kinase B1 (LKB1) and Ca2+/calmodulin-dependent protein kinase kinase (CaMKK). Together, these data suggest that SR4, a novel AMPK activator, may be a promising therapeutic compound for treatment of obesity, fatty liver disease, and related metabolic disorders. == Introduction == Obesity is usually a common metabolic disorder that is rapidly becoming a global public health in adult and pediatric populations, affecting more than 500 million people worldwide in 2013[1]. It is associated with an increased risk of several life-threatening diseases such as type 2 diabetes (T2D), cardiovascular diseases, renal diseases, and multiple types of cancer and may PE859 represent a leading preventable cause of death[2],[3]. Obesity is characterized by pathologic growth of adipose tissues to accommodate Vcam1 extra energy intake through an increase in the number (hyperplasia) and size (hypertrophy) of adipocytes[4], and dysregulation of chronic inflammatory and hormonal signaling pathway responsible for regulation of long-term nutrient metabolism, energy balance, appetite and satiety[5],[6]. Maintaining energy balance depends on the efficiency of tightly regulated mechanisms of energy intake and expenditure. Besides the well-established role of nutrients, hormones and hypothalamic neural circuits, evidence has exhibited that basic cellular metabolic pathways have a major role in the regulation of PE859 whole body energy homeostasis. Among them is usually 5 adenosine monophosphate-activated protein kinase (AMPK), an energy-sensing enzyme that integrates nutrients, hormones, and stress signals to maintain whole body energy homeostasis[7],[8]. AMPK regulates several proteins involved in glucose and lipid metabolism, including phosphorylation and inactivation of enzymes of fatty acid and cholesterol synthesis, as well as activating ATP-generating processes, including the uptake and oxidation of glucose and fatty acids[9][11]. AMPK activation also results in long-term regulation of glycolytic and lipogenic gene expressionviaphosphorylation of transcription factors, co-activators, and co-repressors[7],[12],[13]. Interestingly, knockdown of AMPK1 or AMPK2 subunits led to the development of obesity and insulin resistance in mice[14],[15]. Due to its involvement in the regulation of a variety of metabolic processes and its central role in glucose and lipid homeostasis, AMPK has become an attractive drug target for the treatment of obesity, T2D, fatty liver disease, cancer, and other metabolic diseases[11],[16][18]. Recent studies have exhibited that anti-diabetic drugs such as metformin and thiazolidinediones, as well as phytochemicals/nutraceuticals like resveratrol, curcumin, glabridin and berberine act as AMPK activators and exhibit beneficial effects on metabolic disorders including obesity, diabetes, hyperlipidemia and insulin resistance[7],[11],[18][24]. Our laboratory recently found some novel small molecules with potential anti-cancer activities while screening for compounds with anti-glycation and anti-inflammatory effects. One of these is usually COH-SR4 (SR4), which showed strong anti-proliferative effects against a wide variety of human and animal cancersin vitroandin vivo[25][27]. SR4 was recently shown to activate AMPK and also prevents adipocyte differentiation of mouse 3T3-L1 cells[27]. We therefore tested the hypothesis that long-term (6-week) treatment of SR4 in high-fat diet (HFD)-induced obese mouse, would improve the metabolic alterations in this animal model of human obesity, including hyperglycemia, hyperlipidemia and insulin resistance. Additionally, we examined the effects of SR4 on hepatic and adipose AMPK activation, adipose hypertrophy, liver steatosis, as well as analyzed the.

---